143151-03-5

Basic information

• Product Name: 4-amino-2-fluoro-5-nitrobenzonitrile
• Synonyms: 4-amino-2-fluoro-5-nitrobenzonitrile;4-Cyano-5-fluoro-2-nitroaniline;Benzonitrile,4-amino-2-fluoro-5-nitro-
• CAS NO: 143151-03-5
• Molecular Formula: C₇H₄FN₃O₂
• Molecular Weight: 181.1239632
• Mol File: 143151-03-5.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-amino-2-fluoro-5-nitrobenzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 4-amino-2-fluoro-5-nitrobenzonitrile(143151-03-5)
• EPA Substance Registry System: 4-amino-2-fluoro-5-nitrobenzonitrile(143151-03-5)

Safety Data

• Hazardous Substances Data: 143151-03-5(Hazardous Substances Data)

Usage

Uses

4-Cyano-5-fluoro-2-nitroaniline, can be used in the synthesis of more complex oharmacetucal and biologically active compounds. It is used in the preparation of radiofluorinated quinoxalinedione derivatives as putative ligands of the AMPA receptor.

Upstream product

• 3939-09-1 2,4-difluorobenzonitrile 
• 1336-21-6 ammonium hydroxide 
• 67152-20-9 2,4-difluoro-5-nitrobenzonitrile 

Downstream Products

• 473537-38-1 tert-butyl (4-cyano-5-fluoro-2-nitrophenyl)carbamate 
• 1196074-43-7 4-amino-2-methoxy-5-nitrobenzonitrile 
• 1026971-85-6 4,5-Diamino-2-imidazol-1-yl-benzonitrile 

Relevant articles and documents

METHODS USING HDAC11 INHIBITORS

The present invention provides methods and uses of inhibitors of histone deacetylase 11 (HDAC11) in the treatment of diseases and/or disorders, such as, for example, cell proliferative diseases.

NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS

A compound of Formula (I) is set forth, including pharmaceutically acceptable salts thereof, wherein Het is a 5 or 6-membered heterocycle with -N, -O, or -S adjacent to the -Ar substituent or adjacent to the point of attachment for the -Ar substituent; Ar

2-(2-Hydroxy-3-alkoxyphenyl)-1H-benzimidazole-5-carboxamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors

The development of potent and selective urokinase-type plasminogen activator (uPA) inhibitors based on the lead molecule 2-(2-hydroxy-3-ethoxyphenyl)-1H-benzimidazole-5-carboxamidine (3a) is described.